TimeTeller puts our internal clocks at personalized medicine's center

At-home health testing has historically faced skepticism due to overblown claims and occasional fraud. However, German startup TimeTeller is breaking this mold with a scientifically grounded saliva test kit designed to help anyone understand their circadian rhythm. The company is led by CEO Angela Relógio, a physicist-engineer and molecular biologist who spent years researching oncology, circadian biology, and systems medicine in Germany before transitioning from academia into the private sector.

Relógio maintains a cautious approach regarding what her startup's test can achieve today. Her surname literally means 'clock' in her native Portuguese, and TimeTeller holds massive potential to reduce the debilitating side effects of cancer treatments and improve patient outcomes. By timing medical treatments to coincide with a patient's internal biological clock, therapies can theoretically become much more tolerable and effective.

Despite this grand potential, Relógio is careful to clarify that TimeTeller operates on two distinct timelines. The ultimate long-term goal is to determine precisely when cancer treatments will be tolerated best, moving far beyond generalized categorizations like being a morning person or a night owl. However, the current direct-to-consumer kit will not automatically calculate this for patients independently. Relógio cautions that such complex calculations must be performed for every individual medicine within the strict context of clinical studies.

According to Relógio, TimeTeller initially began accepting direct consumer orders primarily in response to intense demand from longevity clinics. These specialized clinics focus heavily on healthy aging and recognize that granular individual data regarding circadian rhythms can provide personalized advice on sleep, nutrition, light exposure, and physical activity. Furthermore, TimeTeller's foundational science could eventually extend to metabolic diseases like diabetes, neurodegenerative conditions such as Alzheimer’s, athletic performance tracking, and women’s health. Nevertheless, oncology remains the core mission of the enterprise.

The inspiration for TimeTeller struck while Relógio was studying cancer in an academic setting. She frequently observed cancer patients pausing or halting their life-saving treatments entirely due to unbearable side effects. As a dedicated scientist, watching this happen was deeply troubling, especially because she became convinced that part of the underlying problem was not just the medication itself, but precisely when it was administered. This crucial realization drove her to develop the circadian rhythm test that now serves as the foundation of her company.

Driven by absolute conviction, Relógio personally funded the startup's very first patent. She strongly believed that such a vital scientific discovery deserved to escape the confines of academic journals and directly help people in the real world. Originally spinning out from Berlin’s prestigious Charité university hospital, TimeTeller later relocated to Medical School Hamburg. This strategic move provided crucial access to patient demographics, necessary funding, and even a unique safety net: backup employment for the startup's core team of ten employees in case financial hurdles arose.

Fortunately, that safety net may prove entirely unnecessary. Having enlisted biochemist and market access specialist Benjamin Dose as a co-founder, TimeTeller successfully secured a landmark partnership with Techniker Krankenkasse, one of Germany’s largest health insurance providers. This collaboration initially began as a reimbursement agreement covering the cost of the test for specific subsets of cancer patients. Both organizations are now actively preparing to expand the program to reach more of the insurer’s twelve million members. Through careful science and strategic partnerships, TimeTeller is successfully making personalized chronobiology an accessible reality for patients.